These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 35683015)
1. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis. Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015 [TBL] [Abstract][Full Text] [Related]
2. The Ultrastructure of Tissue Damage by Amyloid Fibrils. Koike H; Katsuno M Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762 [TBL] [Abstract][Full Text] [Related]
3. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study. Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270 [TBL] [Abstract][Full Text] [Related]
4. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808 [TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloid aggregation. Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961 [TBL] [Abstract][Full Text] [Related]
6. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation. Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J Elife; 2020 Mar; 9():. PubMed ID: 32151314 [TBL] [Abstract][Full Text] [Related]
7. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics. Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839 [TBL] [Abstract][Full Text] [Related]
8. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis. Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419 [TBL] [Abstract][Full Text] [Related]
9. Thermal stability threshold for amyloid formation in light chain amyloidosis. Poshusta TL; Katoh N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M Int J Mol Sci; 2013 Nov; 14(11):22604-17. PubMed ID: 24248061 [TBL] [Abstract][Full Text] [Related]
10. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis. Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438 [TBL] [Abstract][Full Text] [Related]
13. Light chain amyloidosis - current findings and future prospects. Baden EM; Sikkink LA; Ramirez-Alvarado M Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145 [TBL] [Abstract][Full Text] [Related]
14. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. Bianchi G; Kumar S Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420 [TBL] [Abstract][Full Text] [Related]
15. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis. Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736 [TBL] [Abstract][Full Text] [Related]
16. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis. Manabe S; Iwasaki C; Hatano M; Kametani F; Yazaki M; Nitta K; Nagata M BMC Nephrol; 2018 Nov; 19(1):337. PubMed ID: 30466387 [TBL] [Abstract][Full Text] [Related]
17. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555 [TBL] [Abstract][Full Text] [Related]
18. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348 [TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of systemic light chain AL amyloidosis. Bhutani D; Lentzsch S Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825 [TBL] [Abstract][Full Text] [Related]
20. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]